TECHNICAL FIELD

The present invention relates to an oral pharmaceutical composition comprising fenofibric acid or a pharmaceutically acceptable salt thereof and an alkalifying agent, which has improved bioavailability and a minimized absorption deviation in the gastrointestinal tract.

BACKGROUND ART

Fenofibrate can be used to treat intrinsic hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. It has been known that a daily dose of 300 to 400 mg fenofibrate can reduce the levels of hypercholesterolemia by 20Ëœ25% and hypertriglyceridemia by 40Ëœ50%.

Fenofibrate is metabolized in plasma to the active metabolite, fenofibric acid (chemical name: 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid). Fenofibric acid in plasma is eliminated with a half-life of about 20 hours, and peak plasma levels of fenofibric acid occur in about 5 hours after administration.

Fenofibric acid is known to lower levels of total cholesterol (total-C), low density lipoprotein (LDL-C), apo-lipoprotein B, total triglyceride- and triglyceride-rich lipoprotein (VLDL), high density lipoprotein (HDL), and apo-lipoprotein AI and AII in treated patients.

As fenofibrate and fenofibric acid are hydrophobic and poorly soluble in water, they have low bioavailability and their absorption in the digestive tract increases when administered shortly after a meal (fed conditions), as compared to administration under fasting conditions. In general, retention times in the gastrointestinal tract become much longer in fed conditions. As such, when bioavailability of a drug is influenced by the presence of food in the gastrointestinal tract, it is regarded that the drug exhibits food effect. In case of fenofibrate, as food can increase bioavailability of fenofibrate, failure to take fenofibrate with food may lead to significantly decreased absorption. A commercially available fenofibrate-containing product, TricorÂ® (Abbot), shows an increased absorption rate up to about 35% in fed conditions, compared to administration under fasting conditions. Meanwhile, fenofibric acid has higher solubility at higher pH in the small intestine.

For the reason, a variety of approaches have been attempted to increase the dissolution rate of fenofibrate or to minimize the food effect (e.g., micronization of fenofibrate, addition of surfactants, co-micronization fenofibrate with surfactants).

For example, European Patent No. 256933 describes micronized fenofibrate granules having improved fenofibrate bioavailability. In the granule, the size of crystalline fenofibrate microparticles is smaller than 50 Î¼m and polyvinylpyrrolidone is used as a binder. The European patent also suggests a different type of binders such as methacrylic polymers, cellulose derivatives, and polyethylene glycol. Alternatively, European Patent No. 245933 discloses the preparation of fenofibrate granules using an organic solvent.

European Patent No. 330532 discloses a method for improving fenofibrate bioavailability by co-micronizing fenofibrate with a solid surfactant such as sodium lauryl sulfate. The co-micronized product is formulated into granules by wet granulation in order to enhance the fluidity of powder and make its formulation into gelatin capsules easier.

International Publication No. WO 98/31361 suggests a fenofibrate composition having improved bioavailability, which comprises an inert water-dispersable support coated with a film containing micronized fenofibrate, a hydrophilic polymer (e.g., polyvinylpyrrolidone), and optionally a surfactant. However, as the method requires a substantial amount of polyvinylpyrrolidone and other excipients, only a formulation containing fenofibrate in a small amount of 17.7 wt % can be obtained. Hence, the volume of the final dosage form becomes too large, and thus it is difficult to administer a desired dose of fenofibrate in a sole or complex formulation.

Meanwhile, U.S. Pat. No. 7,259,186 discloses a salt of fenofibric acid selected from the group consisting of choline, ethanolamine, diethanolamine, piperazine, calcium, and tromethamine salt, in order to reduce the food effect on bioavailability. U.S. Pat. No. 152,714 also describes a preparation of choline salt of fenofibric acid in working examples and shows that the food effect was reduced by the ionic strength of the salt.

As noted above, there have been continuous needs for development of a pharmaceutical composition containing fenofibric acid, which has improved water-solubility and high bioavailability with lower food effect, thereby having a minimized absorption deviation in the gastrointestinal tract.

DISCLOSURE OF INVENTION

It is an object of the present invention to provide an oral pharmaceutical composition comprising fenofibric acid which has improved bioavailability and a minimized absorption deviation in the gastrointestinal tract.

In accordance with one aspect of the present invention, there is provided an oral pharmaceutical composition comprising fenofibric acid or a pharmaceutically acceptable salt thereof and an alkalifying agent.

BRIEF DESCRIPTION OF THE DRAWINGS

The above and other objects and features of the present invention will become apparent from the following description of the invention, when taken in conjunction with the accompanying drawings, which respectively show:

FIG. 1: water-solubilities (Î¼g/ml) of fenofibrate, fenofibric acid and choline fenofibrate, as measured in Test Example 1;

FIG. 2: levels (Î¼g/ml) in the blood of rats of fenofibrate, fenofibric acid and choline fenofibrate, as measured in Test Example 2;

FIG. 3: change in the length ratio (aspect ratio) of the major axis/minor axis of the pellet by variation in the weight ratio of the alkalifying agent and fenofibric acid, as observed in Test Example 4;

FIG. 4: dissolution profiles by pH variation of the fenofibric acid pellets and tablets prepared in Examples 13 and 14, and Comparative Examples 10, 12 and 13, as observed in Test Example 5;

FIGS. 5 and 6: dissolution profiles by paddle rotation speed variation of the fenofibric acid pellets and tablets prepared in Example 14 and Comparative Example 12, respectively, as measured in Test Example 6; and

FIG. 7: levels (Î¼g/ml) in the blood of beagles of the fenofibric acid pellets prepared in Comparative Example 10, and Examples 13 and 14, as measured in Test Example 7.

BEST MODE FOR CARRYING OUT THE INVENTION

The oral pharmaceutical composition according to the present invention comprises fenofibric acid or a pharmaceutically acceptable salt thereof, and 0.22 to 1 part by weight of an alkalifying agent based on 1 part by weight of fenofibric acid. The alkalifying agent directly contacts with fenofibric acid or a pharmaceutically acceptable salt thereof, which can increase micro-environmental pH around fenofibric acid upon exposed to the in vivo environment, thereby increasing water-solubility and consequently bioavailability of fenofibric acid.

The oral pharmaceutical composition according to the present invention may be formulated in the form of a pellet which can be filled into a capsule. The pellet may be relatively easily prepared, and it is the most suitable form to be obtained as a coating formulation by coating with a delayed-release coating substrate. Also, the pellet is apt to be simply formulated according to a drug content to be required due to its convenient content control. Especially, in order to minimize the in vivo release deviation of a drug and maintain a constant release rate thereof, the pellet is required to have the form close to a spherical form by way of making the length of the major axis similar to that of the minor axis. For example, the pellet may be of a form having a length ratio of the major axis and the minor axis of 1.5 or less, i.e., a length ratio ranging from 1.0 to 1.5, preferably 1.0 to 1.2. Therefore, the inventive pharmaceutical composition may further comprise a spheronizing additive.

The pellet form of the pharmaceutical composition of the present invention may be prepared by the method comprising the steps of:

(i) first wet-mixing fenofibric acid or a pharmaceutically acceptable salt thereof and an alkalifying agent;

(ii) adding a pharmaceutically acceptable excipient to the first mixture obtained in step (i), and second wet-mixing them; and

(iii) granulating the second mixture obtained in step (ii) into a spherical form using an extruder and a spheronizer.

Optionally, in step (ii), the method may comprise further adding a spheronizing additive to the first mixture. In addition, the method may further comprise coating the granule obtained in step (iii) with a delayed-release coating substrate.

Each of ingredients of the inventive oral pharmaceutical composition is described in detail as follows.

(1) Fenofibric Acid or a Pharmaceutically Acceptable Salt Thereof

Fenofibric acid or its pharmaceutically acceptable salt used as an active ingredient in the present invention is a fenofibrate metabolite, which attributes to substantially decrease a level of plasma triglyceride in a patient suffering from hypertriglyceridemia, and levels of plasma cholesterol and LDL-C in a patient suffering from hypertriglyceridemia or mixed-type hyperlipidemia.

(2) Alkalifying Agent

The alkalifying agent used in the present invention is an additive for improving solubility of fenofibric acid or its pharmaceutically acceptable salt. The alkalifying agent directly contacts with fenofibric acid or a pharmaceutically acceptable salt thereof, which can increase micro-environmental pH around fenofibric acid upon exposed to the in vivo environment, thereby increasing water-solubility and consequently bioavailability of fenofibric acid. Also, the alkalifying agent increases solubility of fenofibric acid or its pharmaceutically acceptable salt in a low pH environment.

Representative examples of the alkalifying agent used in the present invention include alkali metal salts such as calcium salts (calcium carbonate, calcium hydroxide, calcium hydrogen phosphate, calcium phosphate), magnesium salts (magnesium carbonate, magnesium hydroxide, magnesium silicate, magnesium oxide, magnesium aluminate, magnesium aluminum hydrate), lithium salts (lithium hydroxide), potassium salts (potassium hydroxide), sodium phosphate (sodium bicarbonate, sodium borate, sodium carbonate, sodium hydroxide) and the like. Also, a basic additive such as meglumine, arginine and a mixture thereof may be used. More preferably, the alkalifying agent may be calcium carbonate, magnesium carbonate, meglumine, or a mixture thereof.

The alkalifying agent may be employed in an amount ranging from 0.22 to 1 part by weight based on 1 part by weight of the fenofibric acid or a pharmaceutically acceptable salt. When the amount of the alkalifying agent is less than 0.22 parts by weight, the water-solubility of fenofibric acid cannot be achieved to the desired level of at least 1000 ppm; and when more than 1 part by weight, the length ratio of the major axis and the minor axis of the pellet exceeds 1.5, which results in a difficulty in the pellet spheronization, thereby leading to formation of a pellet unsuitable for the coating process.

(3) Delayed-Release Coating Substrate

The fenofibric acid pellet containing the alkalifying agent according to the present invention may be coated with a delayed-release coating substrate. The coating with such a delayed-release coating substrate helps the pellet release a drug at a constant rate until the pellet reaches a high pH region, which brings out a minimized absorption deviation in the gastrointestinal tract.

The delayed-release coating substrate used in the present invention includes a water-insoluble polymer or hydrophobic compound.

The water-insoluble polymer may be selected from the group consisting of hydroxypropylmethylcellulose phthalate (HPMCP), polyvinyl acetate (e.g., KOLLICOAT SR 30D), water-insoluble polymethacrylate copolymers [e.g., poly(ethylacrylate-methylmethacrylate) copolymers (e.g., Eudragit NE30D), poly(ethylacrylate-methylmethacrylate-trimethylaminoethylmethacrylate chloride) copolymers (e.g., Eudragit RSPO) and the like], ethylcellulose, cellulose ester, cellulose ether, cellulose acylate, cellulose diacylate, cellulose triacylate, cellulose acetate, cellulose diacetate, cellulose triacetate, and a mixture thereof; preferably at least one selected from the group consisting of hydroxypropylmethylcellulose phthalate (HPMCP), polyvinyl acetate, poly(ethylacrylate-methylmethacrylate) copolymers, poly(ethylacrylate-methylmethacrylate-trimethylaminoethylmethacrylate chloride) copolymers, ethylcellulose, and cellulose acetate; more preferably at least one selected from the group consisting of hydroxypropylmethylcellulose phthalate (HPMCP), poly(ethylacrylate-methylmethacrylate) copolymers, ethylcellulose, and cellulose acetate.

The hydrophobic compound may be selected from the group consisting of fatty acid, fatty acid esters, fatty acid alcohols, waxes, an inorganic material, and a mixture thereof. The fatty acid and fatty acid esters may be at least one selected from the group consisting of glyceryl palmitostearate, glyceryl stearate, glyceryl behenate, cetyl palmitate, glyceryl monooleate, and stearic acid; the fatty acid alcohols, at least one selected from the group consisting of cetostearyl alcohol, cetyl alcohol, and stearyl alcohol; the waxes, at least one selected from the group consisting of carnauba wax, beeswax, and micro-crystalline waxes; and the inorganic material, at least one selected from the group consisting of talc, precipitated calcium carbonate, dicalcium phosphate, zinc oxide, titanium oxide, kaolin, bentonite, montmorillonite, and veegum. The hydrophobic compound may be preferably at least one selected from the group consisting of glyceryl palmitostearate, glyceryl behenate, stearic acid, cetyl alcohol and carnauba wax, more preferably, at least one selected from the group consisting of glyceryl behenate, stearic acid, and carnauba wax.

The delayed-release coating substrate may be employed in an amount ranging from 0.05 to 0.5 parts by weight based on 1 part by weight of the pellet (the pellet before coated) as a core. When the amount of the delayed-release coating substrate is less than 0.05 parts by weight, no desired delayed-release effects is obtained; and when more than 0.5 parts by weight, the size of the coated pellet becomes too large, thereby causing formation of too big sized capsule.

(4) Spheronizing Additive

The spheronizing additive used in the present invention serves to prepare the pellet which has the form close to a spherical form by controlling the length of the major axis similar to that of the minor axis and to give a constant mechanical coherence thereto. The spheronizing additive includes a natural macromolecule such as carrageenan gum, guar gum, xanthane gum, locust bean gum, gellan gum, arabia gum, agar, alginic acid, alginic acid propylene glycol, sodium alginate, and a mixture thereof.

The spheronizing additive may be employed in an amount ranging from 0.05 to 0.5% by weight based on the total weight of the pellet (the pellet before coated) corresponding to a core. When the spheronizing additive is employed in an amount of less than 0.05% by weight, it is difficult to obtain the desired spheronizing effect; and when in an amount of more than 0.5% by weight, delay of release undesirably occurs or the pellet can be adherent to the production equipments due to its adhesive property in an extrusion process.

Also, the inventive pharmaceutical composition may further comprise a suitable amount of a pharmaceutically acceptable excipient such as a conventional disintegrating agent, a diluent, a stabilizer, a binder, a lubricating agent and the like.

The inventive pharmaceutical composition may be orally administered in a pellet form, and the preparation method thereof comprises the steps of: (i) first wet-mixing fenofibric acid or a pharmaceutically acceptable salt thereof and an alkalifying agent; (ii) adding a pharmaceutically acceptable excipient to the first mixture obtained in step (i), and second wet-mixing them; and (iii) granulating the second mixture obtained in step (ii) into a spherical form using an extruder and a spheronizer.

Optionally, in step (ii), the method may comprise further adding a spheronizing additive to the first mixture. In addition, the method may further comprise coating the granule obtained in step (iii) with a delayed-release coating substrate.

The inventive oral pharmaceutical composition comprising fenofibric acid exhibits improved bioavailability and a minimized absorption deviation in the gastrointestinal tract, and, accordingly, it is useful in treating hyperlipidemia and hypertriglyceridemia.

The following Examples are intended to further illustrate the present invention without limiting its scope.

TEST EXAMPLE 1Solubility Test of Fenofibric Acid, Fenofibrate, and Choline Fenofibrate

Each of fenofibrate (Harman, India), fenofibric acid (Harman, India) and choline fenofibrate was placed in the amount equivalent to 100 mg fenofibric acid in a 100 mL flask. Each of distilled water and artificial intestinal juice (pH 6.8; USP) was added thereto to fill 100 mL, and the mixture was vigorously blended for 1 hr and passed through a 0.45 Î¼m filter, followed by HPLC analysis. The solubilities (ug/ml) of the compounds are shown in Table 1 and FIG. 1 (analysis method: see â€˜Fenofibrateâ€™ in USP).

TABLE 1FenofibrateFenofibric acidCholine fenofibrateDistilled water01651000Artificial intestinal010001000juice (pH 6.8)

As can be seen in Table 1 and FIG. 1, fenofibrate was nearly insoluble in water or other solvents, while the solubility in water of fenofibric acid was higher than that of fenofibrate, but lower than that of choline fenofibrate, showing that the water-solubilites of above compounds are in an order of choline fenofibrate>fenofibric acid>fenofibrate. Meanwhile, fenofibric acid and choline fenofibrate were completely dissolved at pH 6.8, as evidenced by their solubility of 1000 ppm.

For reference, it is recommended to take a drug with 200 to 300 mL of water, and more preferably 240 mL according to the Korean Guideline for Bioequivalence Studies. In addition, considering that the volume of gastric juice in fasting conditions is about 45 mL and the stomach expands up to 1000 mL in fed conditions (Sherwood, Lauralee (1997). Human physiology: from cells to systems. Belmont, Calif.: Wadsworth Pub. Co), high in vivo bioavailability of fenofibrate would be expected when water-solubility of the main component becomes not less than 1000 ppm, such that 200 mg of fenofibrate present in a fenofibrate-containing capsule (e.g., LipanthylÂ®) can be sufficiently dissolved when being taken with 200 mL of water in fasting conditions.

TEST EXAMPLE 2Pharmacokinetic Evaluation of Raw Materials

Each of fenofibrate, fenofibric acid and choline fenofibrate was placed in the amount equivalent to 88 mg fenofibric acid into microcapsules. The microcapsules were orally administered to 7 week-old male SD rats (Sprague Dawley, Samtako, 4 rats per one group, 7 days feeding ad libitum) by using Sonde. Blood samples were taken from the rats in a predetermined time interval, and the respective pharmacokinetic profiles were evaluated. The results are shown in Table 2 and FIG. 2.

TABLE 2CholineFenofibrateFenofibric acidfenofibrateAUC 0-242078.3 Â± 610.52742.2 Â± 218.13477.7 Â± 558.9(Î¼g Â· hr/mL)Cmax (Î¼g/mL)137.2 Â± 37.9209.3 Â± 26.1309.4 Â± 62.2

As evidenced by Table 2 and FIG. 2, the absorption rates were shown to be in an order of choline fenofibrate>fenofibric acid>fenofibrate, which were identical to the solubilities in water obtained in Test Example 1, showing the correlation between the water-solubility and the absorption rate of a drug.

EXAMPLES 1 TO 9 AND COMPARATIVE EXAMPLES 1 to 9Preparation of Fenofibric Acid Pellets Comprising Alkalifying Agents

In order to increase micro-environmental pH around fenofibric acid, fenofibric acid and an alkalifying agent were added in an amount as set forth in Table 3 to a certain amount of water and mixed thoroughly (the first wet-mixing). Then, povidone (BASF, Germany) was added thereto and mixed thoroughly (the second wet-mixing) to obtain a combined mixture. The mixture was extruded through a 0.8 mm-mesh sieve using an extruder (MG-55, Dalton) and spheronized for 3 min using a spheronizer (Spheronizer Q-230T, Dalton), followed by drying at 60Â° C. to obtain pellets.

TABLE 3(unit: mg)Alkalifying agentWeight ratio ofFenofibricMagnesiumalkalifying agent/fenofibricacidMegluminecarbonateCaCO₃PovidoneacidComp. Ex. 113510350.07Comp. Ex. 213520350.15Ex. 113530350.22Ex. 213580350.59Ex. 3135135351.00Comp. Ex. 3135200351.48Comp. Ex. 413510350.07Comp. Ex. 513520350.15Ex. 413530350.22Ex. 513580350.59Ex. 6135135351.00Comp. Ex. 6135200351.48Comp. Ex. 713510350.07Comp. Ex. 813520350.15Ex. 713530350.22Ex. 8135800.59Ex. 91351351.00Comp. Ex. 91352001.48

COMPARATIVE EXAMPLES 10 AND 11Preparation of Fenofibric Acid Pellets Containing no Alkalifying Agent

The procedure of Example 1 was repeated based on the conditions as set forth in Table 4 below, except for using no alkalifying agent.

TABLE 4(unit: mg)Weight ratio ofalkalifyingFenofibricCholineagent/fenofibricacidFenofibratePovidoneacidComp. Ex. 10135350.00Comp. Ex. 11178.7 (135 for350.00fenofibric acid)

EXAMPLES 10 TO 12 Preparation of Fenofibric Acid Pellets Comprising Spheronizing Additives

The procedure of Example 1 was repeated based on the conditions as set forth in Table 5, except for adding carageenan gum (FMC biopolymer), guar gum (Haji dossa) or propylene glycol alginate (ISP) as a spheronizing additive on the second wet-mixing.

TABLE 5(unit: mg)Spheronizing additivepropyleneFenofibriccarageenanglycolMagnesiumacidgumguar gumalginatecarbonateEx. 1013535135Ex. 1113535135Ex. 1213535135

TEST EXAMPLE 3 Comparison of Solubilities of Fenofibric Acid According to the Amount of Alkalifying Agents

The water-solubilities (Î¼g/mL) of fenofibric acid were measured by employing the pellets prepared in Examples 1 to 9 and Comparative Examples 1 to 11 in amounts equivalent to 100 mg fenofibric acid, in accordance with the procedure of Test Example 1. The results are shown in Table 6.

TABLE 6Weight ratio ofalkalifyingWater-agent/fenofibric acidsolubilityComp. Ex. 10.07478Comp. Ex. 20.15740Ex. 10.221001Ex. 20.591000Ex. 31.001002Comp. Ex. 31.481001Comp. Ex. 40.07465Comp. Ex. 50.15733Ex. 40.221001Ex. 50.591002Ex. 61.001003Comp. Ex. 61.481002Comp. Ex. 70.07452Comp. Ex. 80.15727Ex. 70.221002Ex. 80.591001Ex. 91.001002Comp. Ex. 91.481002Comp. Ex. 100.00164Comp. Ex. 110.001000

As can be seen in Table 6, the solubility of fenofibric acid increases as the amount of the alkalifying agent increases. When the weight ratio of alkalifying agent/fenofibric acid is not less than 0.22, the water-solubility of the pellet exceeded the targeted level of the present invention, i.e., 1000 ppm. This result indicates that the pellets of the present invention have the water-solubility of fenofibric acid equivalent to choline fenofibrate, and would have an enhanced in vivo absorption rate.

TEST EXAMPLE 4 Evaluation of Spheronizing Degrees

The length ratios of the major axis and the minor axis (aspect ratios) were measured on the pellets prepared in Examples 1 to 12 and Comparative Examples 1 to 9. The measurement results are shown in Table 7 and FIG. 3.

TABLE 7Alkalifying agent/Fenofibricacid (w/w)Aspect ratioComparative Example 10.071.13Comparative Example 20.151.21Example 10.221.29Example 20.591.32Example 31.001.45Comparative Example 31.481.69Comparative Example 40.071.11Comparative Example 50.151.13Example 40.221.15Example 50.591.18Example 61.001.23Comparative Example 61.481.57Comparative Example 70.071.17Comparative Example 80.151.19Example 70.221.25Example 80.591.26Example 91.001.32Comparative Example 91.481.56Example 101.001.18Example 111.001.19Example 121.001.22

The aspect ratio is an indicator for evaluating a spheronizing degree. The aspect ratio close to 1 means a nearly spherical shape. Generally, when the shape of the pellet is near to a sphere, a coating operation such as delayed-release coating is reproducibly performed, and a mass deviation generated on filling a capsule decreases, thereby resulting in an improvement in productivity (see [Chopra R. et al, Pharm. Dev. Technol. 2002 January; 7(1):59-68] and [Chopra R et al, Eur. J. Pharm. Biopharm. 2002 May; 53(3):327-33]). In contrast, poor spheronization deteriorates the coating efficiency. In particular, when a functional coating such as a delayed-release coating is conducted, a coating deviation occurs, which makes it difficult to reproducibly produce the preparation. An aspect ratio ranging from 1.0 to 1.2 are most preferred, while the pellet having an aspect ratio exceeding 1.5 should be reformed.

It can be seen from the results shown in Table 7 and FIG. 3 that the aspect ratio increased in proportion to the amount of the alkalifying agent. Particularly, the pellets obtained in Comparative Examples 3, 6 and 9 comprising the alkalifying agent in an amount of 1.48 times of that of fenofibric acid showed aspect ratios of 1.5 or more and, accordingly, they are inappropriate for coating. However, the pellets of Examples 10 to 12 using a natural polymer spheronizing additive such as carrageenan gum, guar gum and propylene glycol alginate showed improved spheronizing degrees.

Accordingly, it was demonstrated that the most preferable amount of the alkalifying agent is in a range of 0.22 to 1 part by weight based on 1 part by weight of fenofibric acid.

EXAMPLE 13Preparation of Fenofibric Acid Pellets Comprising Alkalifying Agents

The procedure of Example 10 was repeated except that the alkalifying agent (magnesium carbonate) was used in the amount of 50 mg, to obtain a pellet.

TABLE 8(unit: mg)Example 13Fenofibric acid135Carrageenan gum35Magnesium carbonate50

EXAMPLES 14 TO 16Preparation of Fenofibric Acid Pellets with Delayed-Release Coatings

The pellet obtained in Example 13, as a core, was coated with a delayed-release coating substrate, i.e., hydroxypropylmethylcellulose phthalate (HPMCP, Shinetsu), ethylcellulose (EC, Aqualon) or polyvinyl acetate (PVA, BASF), as shown in Table 9 below. In order to perform a convenient coating, the delayed-release coating substrate was dissolved in a mixture of water and ethanol, and hydroxypropylmethyl cellulose (HPMC, Shinetsu, Japan) and propylene glycol (PEG) were added thereto as coating substrates. The coating process was conducted using a conventional fluidized bed coater, to obtain coated pellets.

TABLE 9(unit: mg)Example 14Example 15Example 16Core pellet220220220(pellet of Example 13)EC32HPMCP32PVA32HPMC121212PEG666EtOH350350350Distilled water353535

COMPARATIVE EXAMPLES 12 AND 13Preparation of Fenofibric Acid Tablet

As shown in Table 10 below, MCC (microcrystalline cellulose, FMC Biopolymer), lactose (DMV pharmaceutical) and/or magnesium stearate as an excipient, and magnesium carbonate as an alkalifying agent were mixed, and the resulting mixture was tableted to obtain tablets comprising fenofibric acid and an alkalifying agent. The tablets were coated using a tablet coater with a coating solution having the same composition as that used in Example 14 (but comprising EC as a delayed-release coating substrate).

TABLE 10(unit: mg)Comparative Example 12Comparative Example 13Fenofibric acid105105Lactose100235MCC135Magnesium5050carbonateMagnesium stearate22EC3232HPMC1212PEG66EtOH350350Distilled water3535

TEST EXAMPLE 5Dissolution Testâ€”(1)

The dissolution rates of the fenofibric acid pellets or tablets obtained in Examples 13 and 14, and Comparative Examples 10, 12 and 13, were tested using the USP paddle II method (rotation rate: 50 rpm). The dissolution test was designed considering the retention time in the stomach, i.e., 1 to 2 hours. First, the pellets or tablets were subjected to a dissolution test in 700 ml of 0.1N HCl for 2 hours, and then 300 ml of a phosphoric acid buffer was added thereto so that the test was continued at pH equal to that of artificial intestinal juice (pH 6.8, USP) (see Dissolution of â€œdelayed-release dosage formâ€ in USP). The results are shown in Table 11 and FIG. 4.

TABLE 11ExampleExampleComparativeComparativeComparativeTime1413Example 10Example 12Example 13(min)Aver.S.D.Aver.S.D.Aver.S.D.Aver.S.D.Aver.S.D.00.00.00.00.00.00.00.00.00.00.0300.00.05.20.20.00.00.00.00.00.0605.00.211.23.31.10.01.10.11.20.112018.21.827.35.21.20.03.80.64.20.615028.32.892.37.589.02.711.42.712.33.018045.24.599.23.5100.23.532.46.542.38.524075.34.0100.14.2100.13.268.610.378.911.836096.55.2100.24.4100.23.495.41.3100.22.0480100.03.0100.24.5100.23.0100.21.5100.21.8

It can be seen from the results shown in Table 11 and FIG. 4 that the pellet obtained in Comparative Example 10, which has neither alkalifying agent nor delayed-release coating, exhibited very low dissolution rate at low pH, but the dissolution rate thereof increased sharply at pH 6.8 due to the relatively high solubility of fenofibric acid. Accordingly, it is predicted that only a part of the drug eluted during staying at the stomach of low pH can be absorbed due to its low solubility, while the absorption of the drug would sharply increase at the small intestine of high pH due to the high solubility of the drug therein. The similar result is observed with the pellet of Example 13 comprising an alkalifying agent, while the solubility of the drug at low pH was significantly improved due to presence of the alkalifying agent. Moreover, with the pellet obtained in Example 14, which further comprises the delayed-release coating, the drug was released slowly at a constant rate, regardless of pH variation. It is expected that such release pattern would minimize the absorption deviation in the gastrointestinal tract in vivo.

TEST EXAMPLE 6Dissolution Testâ€”(2)

The dissolution rates of the fenofibric acid pellets or tablets obtained in Example 14 and Comparative Example 12 were tested according to the same procedure as in Test Example 5, except for changing the rotation rate of the paddle. The results are shown in Table 12, and FIGS. 5 and 6.

TABLE 12Example 14Comparative Example 1250 rpm100 rpm150 rpm50 rpm100 rpm150 rpmTime (min)Aver.S.D.Aver.S.D.Aver.S.D.Aver.S.D.Aver.S.D.Aver.S.D.00.00.00.00.00.00.00.00.00.00.00.00.0300.00.00.00.00.00.00.00.00.00.00.00.0605.00.26.11.76.61.01.10.14.22.36.20.612018.21.818.02.217.72.23.80.614.310.724.313.415028.32.827.61.329.01.011.42.745.310.985.317.118045.24.545.93.447.23.732.46.578.915.897.96.124075.34.075.94.079.73.868.610.399.85.099.81.936096.55.296.95.499.65.095.44.3100.22.0100.62.0480100.03.0100.03.6100.32.9100.21.5100.91.8101.11.8

It can be seen from the results shown in Table 12 and FIGS. 5 and 6 that the dissolution rate of the pellet obtained in Example 14 was rarely influenced by the change of the rotation rate of the paddle, while that of the tablet obtained in Comparative Example 12 was strongly affected thereby. In general, the degree of drug release according to the movement degree of an internal organ can be predicted from the variation in the dissolution rates according to the rotation rate of the paddle. Accordingly, it is expected that tablets such as that obtained in Comparative Example 12 would exhibit a large deviation in the in vivo dissolution rate. In contrast, pellets such as that obtained in Example 14 are predicted to exhibit a small deviation in the in vivo dissolution rate, accordingly, a pellet is considered as a preferable formulation.

TEST EXAMPLE 7Pharmacokinetic Evaluation

Pharmacokinetic evaluation of the fenofibric acid pellets obtained in Comparative Example 10 and Examples 13 and 14 was conducted in beagles. The pellets were administered to three groups each having four beagles, and blood samples thereof were taken at regular time intervals to measure pharmacokinetic (pK) profiles, and the results are shown in Table 13 and FIG. 7.

TABLE 13ComparativeExample 14Example 13Example 10AUC 0-2474366.9 Â± 1989364104.1 Â± 2788242565.3 Â± 18192(ng Â· hr/ml)Cmax (ng/ml)15642.4 Â± 3894â€‚13529.1 Â± 6998â€‚9067.4 Â± 4453â€‚AUC27%43%43%(S.D./Aver.)Cmax25%52%49%(S.D./Aver.)

As shown in Table 13 and FIG. 7, the fenofibric acid pellet obtained in Example 13 comprising an alkalifying agent exhibited the absorption rate higher than that obtained in Comparative Example 10. Meanwhile, the pellet obtained in Example 13 showed the dual pK profiles due to the first absorption in the stomach and the second absorption in the small intestine. In contrast, the pellet obtained in Example 14, which further has a delayed-release coating, exhibits a balanced and high absorption rate. Moreover, from the ratios of the standard deviation (S.D.) to the average value of each of AUC and Cmax, it is understood that the pellet of Example 14 with a delayed-release coating has the small deviation in the absorption rate over the pK stomach and the small intestine. This result demonstrates that the pellet of the present invention would be very useful for treating hyperlipidemia and hypertriglyceridemia.

While the invention has been described with respect to the above specific embodiments, it should be recognized that various modifications and changes may be made to the invention by those skilled in the art which also fall within the scope of the invention as defined by the appended claims.